Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
(OCL) ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session
Related Questions
What timeline and probability are associated with regulatory approval and potential market launch following the conference presentations?
How will the Phase 2 ACUITY trial results for Privosegtor affect Oculis' valuation and near-term stock volatility?
What are the competitive implications of these results compared to other companies developing treatments for diabetic macular edema and acute optic neuritis?